Every claim, every source.

This Australian Institute of Sport study is the most prominent counter-evidence to keto-adapted athletic performance claims. Burke and colleagues randomized 29 elite race walkers to one of three 3-week dietary conditions during intensified training: continuously high carbohydrate availability (HCHO), periodized carbohydrate availability (PCHO — same total intake but timed around training), or low-carbohydrate high-fat (LCHF — under 50 g/day carbs, 78 percent of energy from fat). All three diets were isocaloric. The findings cut against simple "keto is good for endurance" narratives. Peak aerobic capacity (VO2max) improved across all three diets. But race-walking economy — the oxygen cost per unit speed at race-relevant velocities — got worse on LCHF. The keto-adapted walkers needed more oxygen to walk at the same pace, even with elevated fat oxidation. Net result: 10 km race time did not improve on LCHF (about -1.6 percent change, not statistically meaningful) while both carbohydrate-available groups improved 5–7 percent. The conclusion was unambiguous: for elite endurance athletes performing at race-relevant intensities, LCHF impaired performance despite increasing fat oxidation. The paper has been replicated by the same group with different cohorts.

This prospective cohort study followed 1,272 adolescent females over multiple years, identifying which baseline psychosocial and behavioral risk factors predicted the future onset of distinct DSM-5 eating disorders (anorexia nervosa, bulimia nervosa, binge eating disorder, and other eating disorder presentations). The study design enabled differentiation among predictors — body dissatisfaction and dietary restriction predicted multiple eating-disorder onsets, but specific risk-factor profiles also distinguished anorexia onset from bulimia onset from binge-eating onset. Stice and colleagues are among the leading research groups in eating-disorder prevention; this paper supplies one of the cleaner empirical bases for who is at elevated risk for which eating-disorder presentation, with implications for how broader nutrition interventions should screen and refer at-risk participants.

This Cell review by Saxton and David Sabatini — Sabatini being one of the original co-discoverers of mTOR — is the most-cited modern synthesis of mTOR signaling biology. The paper traces how mTOR (mechanistic target of rapamycin) integrates four classes of inputs: nutrients (amino acids, especially leucine and arginine), growth factors (insulin, IGF-1), cellular energy state (AMPK senses ATP:AMP), and stress signals. mTOR exists as two complexes: mTORC1, which controls protein synthesis, lipid synthesis, and inhibits autophagy; and mTORC2, which controls cytoskeletal organization and Akt phosphorylation. The review explains how mTORC1 activation drives anabolic programs (cell growth, protein synthesis) while suppressing catabolic programs (autophagy, lipolysis). Conversely, mTORC1 inhibition — by fasting, by rapamycin, by amino acid restriction, or by genetic loss — releases autophagy, increases lipolysis, and engages stress-resistance programs. The paper documents how dysregulated mTOR signaling drives cancer (mTOR is hyperactivated in most tumors), diabetes (mTORC1 contributes to insulin resistance), and aging (mTOR inhibition extends lifespan in every model organism tested). Therapeutic targeting of mTOR is an active drug-development area.

This randomized pilot study asked the cleanest possible head-to-head question for intermittent fasting: when matched for the goal of weight loss, does alternate-day fasting beat ordinary daily caloric restriction? Adults with obesity (BMI ≥30, age 18–55) were randomized to either zero-calorie alternate-day fasting (ADF, n=14) or moderate daily caloric restriction (CR at -400 kcal/day, n=12) for 8 weeks, followed by 24 weeks of unsupervised follow-up. The ADF arm achieved a substantially larger calculated energy deficit (about 376 kcal/day greater than CR), yet the actual weight loss was statistically indistinguishable: ADF -8.2 kg vs CR -7.1 kg over 8 weeks. Body composition, lipids, and insulin sensitivity index showed no significant between-group differences. Safety was strong — no adverse effects, 93 percent completion in the ADF arm. Twenty-four-week unsupervised follow-up showed similar weight regain in both groups, but the ADF arm trended toward more favorable lean-mass preservation. The honest conclusion: ADF is a safe and tolerable alternative to daily restriction with equivalent short-term outcomes, not a superior intervention.

This eight-week randomized trial enrolled 34 resistance-trained males and assigned them either to a 16:8 time-restricted-feeding pattern (eating window 1pm to 8pm) or to a normal-eating-pattern control while continuing standardized resistance training across both arms. The TRF group showed reductions in fat mass, fasting glucose and insulin, IGF-1, leptin, and inflammatory markers (IL-6, TNFα), and an improved testosterone-to-cortisol ratio, while maintaining muscle area and maximal strength on standard one-rep-max testing. Total energy and protein intake were matched approximately between groups. The study is one of the cleaner demonstrations that an intermittent-fasting-style eating pattern can be combined with resistance training without performance decrement and with favorable body-composition and biomarker changes in already-trained adults.

The FASTER (Fat-Adapted Substrate utilization in Trained Elite Runners) study compared 20 elite ultra-endurance athletes — 10 habitually consuming a high-carbohydrate diet (59 percent carbs) and 10 long-term keto-adapted (10 percent carbs, 70 percent fat, average 20 months on the diet) — across maximal and submaximal exercise testing. The headline finding was record-setting: peak fat oxidation in the keto-adapted athletes was 2.3-fold higher than in the carb-adapted group (1.54 vs 0.67 grams per minute), the highest fat-oxidation rates ever recorded in humans during exercise. During submaximal exercise (3-hour run at 64 percent VO2max), fat contributed 88 percent of the energy in keto-adapted athletes versus 56 percent in carb-adapted athletes. Notably, muscle glycogen utilization and post-exercise glycogen repletion were similar between groups despite the dramatic substrate-source shift — meaning keto-adapted athletes used proportionally less carbohydrate from glycogen stores during the run, so their glycogen actually lasted longer. The paper transformed how the field thinks about athletic substrate use: humans can adapt to fat as their dominant fuel without losing the ability to use carbohydrate when it matters.

This Cell Metabolism paper from Valter Longo's USC group introduced the fasting-mimicking diet (FMD) — a 5-day periodic dietary protocol designed to deliver fasting's molecular benefits while keeping participants able to consume modest amounts of plant-based food. The paper has two parts. In aged mice, monthly FMD cycles for several months produced multi-system regeneration: hippocampal neurogenesis rose, IGF-1 dropped, PKA activity decreased, NeuroD1 expression increased, and cognitive performance improved on standard mouse cognition tests. In a 38-participant pilot human RCT, three monthly FMD cycles (each 5 days) produced reductions in body weight, body fat, blood pressure, fasting glucose, and IGF-1 without significant adverse events. The paper is foundational because it bridged rodent CR research and practical human protocol design — providing a structured, safe framework for delivering fasting benefits without continuous calorie restriction. Longo subsequently commercialized the protocol as ProLon, a packaged 5-day FMD product. The paper's data quality is solid but the commercial development complicates how it should be cited.

This Canadian government laboratory study tested 52 canned fish products from the 2014 Canadian retail market for bisphenol A (BPA) and three related compounds (BPB, BPE, BPF) using gas chromatography mass spectrometry. The headline finding: BPA was detectable in every one of the 52 products, but at substantially lower levels than a comparable study from five years earlier. The concentration range was 0.96 to 265 nanograms per gram, with an average of 28 ng/g. Three of the four BPA analogues were essentially absent — BPB and BPE were not detected in any product, and BPF appeared in only four samples at low concentrations (1.8 to 5.7 ng/g) — suggesting BPA is still the dominant epoxy resin used in current can liners. The few outliers above 100 ng/g came from a single newly-marketed brand, indicating that brand-level differences in liner formulation drive most of the variation. Industry-wide, the data show measurable downward progress in canned-fish BPA exposure.

Quantitative review pooling adipose tissue fatty acid composition data from US-based studies across five decades. The authors document a near-linear rise in adipose linoleic acid (LA) from approximately 9.1% of total fatty acids in 1959 to 21.5% by 2008 — a 136% relative increase. The rise correlates strongly with dietary LA intake estimates over the same period (R² = 0.81). The paper also estimates an adipose LA incorporation half-life of approximately 680 days, meaning dietary changes take about two years of consistent intake to fully manifest in tissue composition. The data establishes that dietary LA is a major determinant of long-term tissue LA, and that tissue LA changes slowly enough that short-term dietary interventions show muted adipose effects.

This EFSA Scientific Committee statement weighs the cardiovascular and neurodevelopmental benefits of fish consumption against the risks of methylmercury exposure across the European population. It builds on EFSA's 2012 opinion which set the tolerable weekly intake (TWI) for methylmercury at 1.3 µg/kg body weight — meaning a 70 kg adult can safely consume about 91 µg/week. The 2015 statement identifies the dominant European mercury sources by species: tuna (the largest single contributor in adult diets), swordfish, cod, whiting, and pike. Notably, sardines are not on this high-mercury list. The statement acknowledges new epidemiological data (Seychelles cohort) showing that the long-chain omega-3s from fish may counteract some methylmercury toxicity — a benefit-risk tradeoff that favors lower-mercury species like sardines. EFSA's conclusion is risk-tiered: vulnerable groups (pregnant women, children, high-fish consumers up to 6× TWI) should choose lower-mercury species; the general adult population can consume fish at moderate intake without exceeding the TWI.

This study established a foundational point in microbiome research: dietary changes alter gut microbial composition rapidly and reproducibly. Ten participants alternated between an entirely animal-based diet (meat, eggs, cheese) and an entirely plant-based diet (grains, legumes, fruits, vegetables) for five days each. Microbiome composition shifted within 24 hours of dietary change and reverted within 48 hours of returning to baseline diet. The animal-based diet specifically increased the abundance of bile-tolerant microorganisms (Bilophila wadsworthia, Alistipes putredinis, Bacteroides) and decreased the abundance of Firmicutes that metabolize plant polysaccharides. Functional metagenomic analysis confirmed corresponding shifts in microbial gene expression. The paper is the canonical reference for the rapid-response biology of the human gut microbiome to dietary substrate change and for the bidirectional, plastic nature of these shifts.

This Trends in Endocrinology and Metabolism review reframes how the body uses ketone bodies — particularly β-hydroxybutyrate (βOHB) — beyond their traditional role as fuel. Newman and Verdin synthesize evidence that βOHB acts as a signaling molecule through at least two mechanisms. First, βOHB binds at least two cell-surface G-protein-coupled receptors (HCAR2/GPR109A and FFAR3/GPR41), modulating lipolysis, sympathetic tone, and metabolic rate. Second, βOHB directly inhibits class I histone deacetylases (HDACs), which means circulating ketones during fasting or ketogenic diets alter gene expression by changing how DNA is packaged. The review traces implications for caloric restriction, longevity, and aging-related diseases. The paper is a key citation for any claim that ketogenic diets and fasting do work beyond "running on fat instead of carbs" — they trigger gene-expression changes via epigenetic mechanisms with downstream effects on stress resistance, inflammation, and metabolic flexibility. The review is highly cited and has shaped how mechanistic ketosis research is framed.

This Cell Metabolism paper combined a large NHANES-based human cohort (2,253 adults followed over 18 years) with mouse experiments to ask whether high protein intake — especially animal protein — drives cancer and mortality risk via IGF-1 and growth-hormone signalling. The headline finding is age-dependent. In adults aged 50–65, those reporting high protein intake (≥20 percent of calories from protein) had a 75 percent higher overall mortality and a fourfold higher cancer death risk over the next 18 years compared to low-protein eaters (under 10 percent of calories). The effect was largely abolished when the protein came from plant sources rather than animal sources. After age 65, the relationship reversed: high protein became protective for cancer and overall mortality — though high protein at any age was associated with a fivefold increase in diabetes mortality. Mouse experiments supported the mechanism: high-protein diets accelerated tumour growth and elevated IGF-1, while protein restriction did the opposite. The interpretation is that protein's relationship with longevity is not monotonic; it depends on age, on the protein source, and on what's being optimized for.

This influential review synthesizes the global picture of forage-fish populations — small pelagic species including sardines, anchovies, herring, menhaden, and capelin — that occupy a central position in marine food webs as the primary trophic link between zooplankton primary production and predator species (larger fish, marine mammals, seabirds). The authors estimate global forage-fish landings at roughly 30 million tonnes per year, with about 90% of that catch directed to non-direct-human-consumption uses, primarily fishmeal and fish oil for aquaculture. The review documents the ecosystem services provided by forage fish, the population dynamics that make them sensitive to over-exploitation, and the co-management requirements (precautionary catch limits, prey-reserve setting) needed to balance fishery yield with ecosystem integrity. The paper is widely cited in conservation policy and is foundational reading for anyone evaluating sardine sustainability in the context of broader marine ecosystem management.

Philip Calder is the leading authority on omega-3 fatty acids and inflammation, and this 2013 BJCP review is his most cited synthesis. The paper traces the multiple mechanisms by which EPA and DHA modulate inflammatory responses: incorporation into cell-membrane phospholipids alters which substrates are available for eicosanoid synthesis (prostaglandins, leukotrienes); direct inhibition of leukocyte chemotaxis, adhesion-molecule expression, and T-cell reactivity; reduced inflammatory cytokine production (TNF, IL-1β, IL-6); disruption of lipid rafts that anchor TLR4 signaling; and generation of pro-resolution lipid mediators (resolvins, protectins) that actively terminate inflammation rather than just dampen it. The paper distinguishes "nutrition-dose" effects (typical 1–2 g/day EPA+DHA from regular fish intake, modest anti-inflammatory shifts) from "pharmacology-dose" effects (3–4 g/day or higher, with measurable effects on rheumatoid arthritis and other clinical inflammatory conditions). The clinical evidence base is strongest for rheumatoid arthritis; weaker and inconsistent for inflammatory bowel disease and asthma.

The 2012 European Union health-claim regulation that defines the regulatory threshold for what counts as a polyphenol-active olive oil. The claim — "olive oil polyphenols contribute to the protection of blood lipids from oxidative stress" — is authorised only for olive oils that deliver at least 5 milligrams of hydroxytyrosol and its derivatives (oleuropein complex and tyrosol) per 20 grams of olive oil consumed. That works out to a tissue-relevant 250 mg per kilogram of olive oil at the daily-intake reference of 20 g. The claim is supported by a body of EFSA-reviewed mechanistic and intervention evidence on phenolic compounds and oxidative stress markers, and is the most widely cited regulatory basis for the "extra virgin olive oil polyphenols are different from refined olive oil" distinction. The regulation is also the EU's reference point for "extra virgin" olive oil quality grading more broadly (acidity ≤0.8%, panel test, polyphenol content). Refined olive oil typically loses 84–87% of polyphenol content during refining.

This consensus review summarizes the human health-effect literature on low-level methylmercury exposure — the form of mercury delivered by dietary fish consumption. The authors evaluate evidence on neurodevelopmental, cardiovascular, neurological, and immunological endpoints across multiple populations and exposure ranges. Their conclusions are nuanced: childhood neurodevelopmental endpoints (subtle decrements in cognitive and motor performance in cohorts with prenatal exposure above background) are the most consistently supported across cohort studies; adult cardiovascular endpoints show much weaker and less consistent evidence; mercury's interaction with the omega-3 benefits of fish consumption complicates the simple dose-response picture for both endpoints. The review distinguishes high-mercury species (tilefish, swordfish, large tuna, shark, king mackerel — to be limited especially in pregnancy) from low-mercury species (small pelagics including sardines, anchovies, salmon — which deliver omega-3 benefits with low mercury exposure). The paper is widely cited in regulatory mercury-exposure guidance.

This study tested 17 different brands of canned sardines, sourced from six countries and bought at retail in eastern Kentucky, for the four most concerning heavy metals in fish: arsenic, cadmium, lead, and mercury. Each brand was analyzed as a composite of 3 to 4 fish using standard atomic-absorption laboratory methods. The headline finding for sardines was clear: mercury was below the 0.09 microgram-per-gram detection limit in every sample tested. That is well under the 1.0 microgram-per-gram FDA action level for predatory fish like tuna and swordfish, and roughly a tenth of the typical canned-tuna averages reported in FDA surveillance data. Arsenic was the highest of the four metals on average (1.06 µg/g), with the highest values appearing in samples from Norway and Thailand; cadmium was highest in Moroccan brands; lead was highest in Canadian brands. The study supports the narrow but important claim that commercial canned sardines, across multiple sourcing countries, are a low-mercury fish.

This meta-analysis pooled 11 randomized controlled trials with 618 total participants to ask whether omega-3 fish oil supplements improve insulin sensitivity in adults. Across all studies and measurement methods, the answer was essentially no. The overall standardized effect size was 0.08 (95% confidence interval -0.11 to 0.28) — statistically indistinguishable from zero. One subgroup analysis was the exception. When researchers used HOMA-IR — a calculation from fasting glucose and insulin — omega-3 supplementation showed a small but statistically significant improvement (effect size 0.30, CI 0.03 to 0.58). On more direct measures of insulin sensitivity, including the euglycemic clamp, the effect was absent. The honest read: at the doses and durations studied, typically 1 to 4 grams of EPA plus DHA per day for weeks to months, omega-3 supplements do not reliably improve insulin sensitivity in adults — though a small HOMA-IR signal exists.

Seyfried and Shelton restate and develop the metabolic theory of cancer first proposed by Otto Warburg, arguing that the origin and progression of cancer is best understood as a mitochondrial-respiratory dysfunction that drives the cellular dependence on glycolysis — the Warburg effect — observed in the majority of tumors. The review compiles evidence from cancer cell biology, tumor metabolism, and animal models suggesting that interventions which restrict glucose availability (caloric restriction, ketogenic diets, multi-day fasting) or that pressure tumor cells through mitochondrial dysfunction may slow tumor growth or sensitize tumors to conventional therapy. The authors propose specific therapeutic implications and discuss the evidence base for ketogenic and caloric-restriction interventions as adjunctive cancer therapy. The review has been influential among researchers exploring metabolic approaches to cancer and is cited heavily in popular content connecting fasting and ketogenic eating to cancer outcomes — sometimes carefully, often less so.